![]()
|
|
||||||||
J. Biol. Chem., Vol. 277, Issue 22, 19658-19664, May 31, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the Departments of
Received for publication, January 22, 2002, and in revised form, February 21, 2002
Peptidoglycan recognition proteins (PGRPs)
constitute a recently characterized family of pattern-recognition
molecules that are conserved from insects to humans and are implicated
in mammalian innate immunity. Here we report the isolation,
characterization, cDNA cloning, and antimicrobial activities of a
bovine PGRP ortholog termed bovine oligosaccharide-binding protein
(bOBP). Milligram quantities of bOBP were purified from peripheral
leukocytes, thus allowing for the characterization of the disulfide
array and for determining the in vitro antimicrobial
activities of the native protein. Of the tissues analyzed, bOBP
mRNA was detected only in bone marrow where the protein is
synthesized as a 190 amino acid precursor. The mature 169 amino acid
protein is stored in the cytoplasmic granules of neutrophils and
eosinophils but is absent from lymphocytes, monocytes, and platelets.
bOBP was microbicidal for Gram-positive and Gram-negative bacteria and
yeast at low micromolar concentrations. The finding that bOBP was
microbicidal for organisms in which peptidoglycan is absent
(Cryptococcus neoformans) or buried (Salmonella
typhimurium) indicates that previous conclusions about the
specificity of peptidoglycan recognition proteins must be reevaluated
and suggests that other envelope components may mediate the
antimicrobial action of PGRP family members.
Studies over the past two decades have revealed that
antimicrobial innate immunity plays a critical role in host defense
mediated in part by pattern-recognition proteins and microbicidal
effector molecules that contain infection prior to an adaptive immune
response (1). Pattern-recognition proteins distinguish invading
microbes by identifying conserved microbial structures that are not
expressed by host cells (2). Microbial killing is mediated by
granulocytes and macrophages that produce oxygen- and nitrogen-derived
toxins (3, 4) as well as microbicidal proteins and peptides (1).
Among the pattern-recognition proteins of innate immunity are
lipopolysaccharide
(LPS)1-binding protein and
bactericidal/permeability-increasing protein, molecules that bind LPS
by amino-terminal structures conserved between the two proteins (5, 6).
Bactericidal/permeability-increasing protein is potently bactericidal
for Gram-negative bacteria (7, 8) and neutralizes the inflammatory
properties of LPS (9). In contrast, LPS-binding protein is not
bactericidal and activates an inflammatory response in myeloid cells
upon LPS binding (10, 11). Toll-like receptors (TLRs) conserved from
insects to humans (12) are key elements of innate immunity (13, 14).
More than ten mammalian TLRs have been identified, each of which may have pattern-recognition functions (15). For example, TLR2 recognizes Gram-positive bacteria by binding peptidoglycan or lipoteichoic acid
(15, 16), TLR4 identifies Gram-negative bacteria through LPS
interactions (15, 17, 18), TLR5 recognizes flagellin (15, 19), and TLR9
identifies bacterial (CpG)DNA (15, 20). TLR-ligand complexes
signal the induction of inflammatory cytokines and chemokines.
Mannose-binding protein is a soluble pattern-recognition protein found
in the serum of all mammals studied (21). A collectin, mannose-binding protein activates complement (21) and opsonizes microbes (22) by binding to carbohydrate moieties of bacterial and
fungal cell envelopes. Humans deficient in circulating mannose-binding protein demonstrate increased vulnerability to a number of microbial pathogens (21, 23).
Peptidoglycan recognition proteins (PGRPs) are recently characterized
components of innate immunity, which are reported to bind specifically
to peptidoglycan moieties. These studies were the basis for concluding
that PGRPs selectively contribute to innate immunity by detecting
Gram-positive bacteria (24, 25). Silkworm PGRP, the first member of the
family, was implicated in the innate immune response by its ability to
trigger the prophenoloxidase cascade in the presence of peptidoglycan
or its glycan moiety (26, 27). Orthologous proteins have been found in
other lepidopteran insects (28-30) and in Drosophila (31)
wherein PGRP gene expression is up-regulated in larvae inoculated with
Gram-negative bacteria (25, 28, 31).
Mammalian PGRPs have been reported in humans (24, 26, 28), mice (26,
28), rats (GenBankTM accession number AF154114), and camels
(GenBankTM accession number AJ131676). PGRP mRNAs have
been localized to human and mouse bone marrow and polymorphonuclear
leukocytes (26, 28) but not to lymphocytes or monocytes (26).
Genomic analysis has determined that there are four human genes (24) and at least eight Drosophila genes (31) that have
significant PGRP homology. Three of the human genes and three of the
Drosophila genes predict products with transmembrane domains
(24, 31).
In this study, we isolated several milligrams of a bovine PGRP, which
we have termed oligosaccharide-binding protein because it was found to
kill microorganisms in a peptidoglycan-independent manner. The
precursor and mature protein structures, including the conformation of
the tri-disulfide array, were determined. Furthermore, tissue
expression analysis and immunolocalization studies were performed to
ascertain the sites of biosynthesis and the storage of bOBP.
Bovine Granulocytes--
Granulocytes were purified from fresh
citrated bovine blood (dairy cattle) as described previously (32).
Preparations contained an average of 1 × 109
cells/liter of whole blood of which 93 ± 3% were neutrophils and
4 ± 1% were eosinophils. Some granulocyte preparations were treated with 2 mM diisopropylfluorophosphate (33) or
protease inhibitor mixture tablets (CompleteTM EDTA-free,
Roche Molecular Biochemicals) prior to protein extraction. Eosinophil-enriched populations of granulocytes were obtained by
centrifugation over a Percoll continuous density gradient prepared according to the manufacturer's directions (Amersham Biosciences). 4 × 108 bovine granulocytes suspended in Hanks'
balanced salt solution plus Ca2+ and Mg2+ were
layered over the gradient and centrifuged at 7500 × g
for 20 min at 4 °C from which two distinct bands were formed. The less dense fraction, which contained ~35% eosinophils, was used for
immunocytochemistry (see below). Cytoplasmic granule preparations were
produced by nitrogen cavitation of granulocytes as described previously
(34). The cavitate was centrifuged at 700 × g at 4 °C for 10 min, and the granule-containing supernatant was
collected. Granules were harvested by centrifugation at 27,000 × g at 4 °C for 40 min.
Purification of bOBP-derived Peptide-13
(BDP-13)--
Cytoplasmic granules derived from
diisopropylfluorophosphate-treated leukocytes were extracted with 1 ml
of ice-cold 10% acetic acid/2 × 109 cell
equivalents. After stirring on ice for 18 h, suspensions were
clarified by centrifugation at 27,000 × g at 4 °C
for 20 min. Supernatants were subjected to size exclusion
chromatography on a Bio-Gel P-60 column as described previously (32).
Low molecular mass components (<10 kDa) identified by SDS-PAGE
were further resolved by C18 reversed-phase high pressure
liquid chromatography (RP)-HPLC, and fractions with antimicrobial
activity were collected as described previously (32). BDP-13 among the
low molecular weight antimicrobial peptides obtained was characterized
by automated Edman sequencing on an Applied Biosystems 475A instrument
configured with on-line phenylthiohydantoin amino acid analysis
(32). The primary sequence was confirmed by comparison with the
sequence predicted from the corresponding cDNA (see below) and by
biochemical comparison with a synthetic congener (see below). Purified
peptide was lyophilized, dissolved in 0.01% acetic acid at 100-500
µg/ml, and stored at Peptide Synthesis and Antibody Production--
BDP-13 was
synthesized with a Milligen 9050 peptide synthesizer as described
previously (35, 36) on Fmoc-L-valine-polyethylene glycol-polystyrene resin (Millipore, Milford, MA). Side chain protecting groups were 2,2,5,7,8-pentamethylchroman-6-sulfonyl for
arginine, trityl for glutamine and histidine,
tert-butoxycarbonyl for lysine, and tert-butyl
for tyrosine. Isoleucine was double-coupled. Following cleavage and
deprotection at 22 °C for 4 h with reagent K (trifluoroacetic
acid/thioanisole/ethanedithiol/phenol/water (82.5:5:2.5:5:5)),
the peptide was purified by C18 RP-HPLC water/acetonitrile gradients and quantified by amino acid analysis (32, 35). Purified
synthetic BDP-13 was indistinguishable from natural BDP-13 by acid
urea-PAGE, analytical RP-HPLC, and in antimicrobial assays.
Synthetic BDP-13 (5 mg) was conjugated to 5 mg of chicken ovalbumin
using the glutaraldehyde method as described previously (37). The
BDP-13-ovalbumin conjugate was suspended in phosphate-buffered saline
and used to immunize two New Zealand White rabbits (Zymed Laboratories Inc., South San Francisco, CA). Serum samples were collected after 10 weeks when the specific antibody titer, as determined by enzyme-linked immunosorbent assay, was ~1:5000. IgG was
prepared from antiserum by DEAE-Econo-Pac chromatography (Bio-Rad) per
the manufacturer's instructions.
Isolation and Characterization of bOBP--
Acid extracts of
1 × 109 cell equivalents of bovine leukocytes or
granule preparations were loaded onto a 10 × 25 cm Delta Pak
RP-HPLC C18 cartridge equilibrated in 0.1% trifluoroacetic acid (solvent A) at a flow rate of 10 ml/min. A linear gradient of
acetonitrile containing 0.1% trifluoroacetic acid (solvent B) was
applied at 2%/min from 0 to 37%, 0.1%/min from 37 to 38%, and
0.167%/min from 38 to 40%. 10-ml fractions were collected, lyophilized, and resuspended in 0.01% acetic acid. Samples containing bOBP were identified by Dot Blot analysis (as described below) using
anti-bOBP IgG (as described above), and pure bOBP was obtained following a second round of RP-HPLC. Purity was confirmed by SDS-PAGE, acid-urea PAGE, and analytical RP-HPLC. Quantitation and composition analysis of bOBP was determined by amino acid analysis performed on 6 N HCl hydrolysates at 150 °C for 2 h using the
AccQTag system (Waters, Milford, MA) according to the manufacturer's
directions. Subsequent quantification of bOBP was determined
spectrophotometrically (1 mg/ml = 1.28 A280). Purified protein was lyophilized,
dissolved in 0.01% acetic acid at 2 mg/ml, and stored at
bOBP and trypsin digestion fragments of bOBP (see below) were analyzed
by matrix-assisted laser desorption ionization time-of-flight mass
spectroscopy (MALDI-TOF MS) on a VOYAGER DE-PROTM mass
spectrometer in the linear mode. Samples (~3 pmol each) were mixed
with equal volumes of
Partial amino acid sequence was obtained by automated Edman degradation
of cyanogen bromide cleavage fragments of bOBP on a Hewlett Packard
1100 instrument (UCI Biotechnology Research Facility, Irvine, CA) (32).
The sequencer cartridge loaded with 300 pmol of bOBP was soaked in a
solution of 10% cyanogen bromide in 90% formic acid for 2 h at
room temperature. The cartridge was then washed with water, and the
eluted material was diluted to <5% formic acid, reapplied to the
cartridge, and sequenced. The internal sequences were compared with the
amino acid sequence deduced from the bOBP cDNA (as described below).
Disulfide Connectivities--
Two nanomoles of bOBP was digested
for 42 h at 37 °C with 1 µg of TPCK-treated trypsin in 50 µl of 0.1 M pyridine acetate, pH 6.6. The reaction was
terminated by acidification with trifluoroacetic acid. Half of the
digest was directly analyzed by RP-HPLC on a 4.6 × 250-mm
C18 column equilibrated in 0.1% trifluoroacetic acid (solvent A) at a flow rate of 1 ml/min. A linear gradient of
acetonitrile containing 0.1% trifluoroacetic acid (solvent B) was
applied at 0.5%/min for 90 min, and 1-ml fractions were collected. The
other half of the tryptic digest was lyophilized, dissolved in 20 µl of 6 M guanidine hydrochloride, 0.2 M Tris-HCl,
2 mM NaEDTA, pH 8.2, purged with nitrogen, and incubated at
50 °C for 30 min. The sample was reduced with 390 µM
dithiothreitol for 4.5 h at 50 °C and alkylated with 3-fold
excess iodoacetamide for 10 min in the dark. Excess alkylating reagent
was quenched with dithiothreitol. The reduced and alkylated tryptic
digest was analyzed by RP-HPLC under the same conditions as the
non-reduced digest. A comparison of the two chromatograms identified
three disulfide-containing fractions in the untreated digest. These
three fractions were characterized by MALDI-TOF MS and automated Edman degradation.
cDNA Cloning--
Total RNA was isolated from bovine bone
marrow by guanidium thiocyanate-phenol extraction (39). Total RNA (1 µg) was used to synthesize cDNA, and 3'-RACE was performed
according to the manufacturer's protocols (Invitrogen) using a
degenerate gene-specific primer, 5'-CARCARTGGCCNCAYTAYMG-3'.
PCR amplification was carried out using the following cycling
parameters: 95 °C for 1 min; 55 °C for 1 min; and 72 °C
for 1 min for 35 cycles. Subsequently, 1 µg of total RNA
was subjected to cDNA cloning and 5'-RACE according to
manufacturer's directions with the gene-specific primer
5'-TGGGATGGGTGGGGTGTGAGAAGACGGACAGGCCCTCACACGCGG-3'. PCR-amplified RACE products were subcloned and sequenced as
described previously (37). Once the 5'- and 3'-ends of the BDP-13
cDNA were known, a PCR product corresponding to the full-length
BDP-13 precursor sequence was generated and characterized by sequence analysis. Sequence data were analyzed using Geneworks 2.5.1 (IntelliGenetics, Mountain View, CA). Amino acid sequences were
analyzed using BLAST and Swiss Protein data bases. Protein and peptide
theoretical masses were calculated by the ExPASy PeptideMass program
(40).
Western Blot and Dot Blot Analyses--
Acid extracts of bovine
leukocytes, extracts of leukocyte granules, and purified bOBP were
lyophilized, boiled for 2 min in dithiothreitol-containing SDS-PAGE
sample buffer, subjected to Tricine-SDS-PAGE (12.5% acrylamide), and
transferred to 0.22-µm nitrocellulose membranes (MSI, Westborough,
MA) using the semi-dry electroblotting technique (41). For Dot Blot
analyses, RP-HPLC fractions were subjected to rotoevaporation briefly
to remove acetonitrile, and they were applied in 1-µl aliquots to
0.22-µm nitrocellulose membranes. Western blot and Dot Blot membranes were fixed in 0.2% glutaraldehyde, quenched with 1 M
NH4Cl, and incubated with 1:1000 anti-bOBP IgG or anti-bOBP
IgG preabsorbed with BDP-13. Immunoreactive bands or Dots were detected
with 1:100,000 goat anti-rabbit IgG conjugated to horseradish
peroxidase using SuperSignal West Pico substrate (Pierce). Blots
were developed by exposure to x-ray film or using digital imaging
(Alpha Innotech, San Leandro, CA).
Immunohistochemistry--
Slides of eosinophil-enriched
leukocytes were prepared on a cytocentrifuge, fixed in 4%
paraformaldehyde for 10 min at 4 °C, and stored at 4 °C in 70%
ethanol. Slides were rehydrated for 5 min in 1× phosphate-buffered
saline and treated with Fc receptor blocking reagent (Innovex
BioSciences, Richmond, CA) for 20 min and then with 1% normal goat
serum for 20 min. Following incubation with 1:40 anti-bOBP IgG for 60 min at room temperature, slides were developed using biotinylated goat
anti-rabbit IgG and a Vectastain ABC glucose oxidase kit (Vector
Laboratories, Burlingame, CA) according to the manufacturer's
instructions. Nuclear Fast Red was used as counterstain. Negative
control incubations were performed using preimmune IgG and anti-bOBP
IgG preabsorbed with BDP-13.
Northern Blot Analysis--
Total RNA from various bovine
tissues was extracted and subjected to Northern blot analysis as
described previously (42). Gel-purified bOBP cDNA probes were
32P-labeled by random priming. A mouse GAPDH cDNA
probe (Ambion, Austin, TX) was used as a control for RNA loading and
integrity. The membrane was stripped and exposed to film to ensure the
removal of bOBP probe prior to hybridization with GAPDH cDNA.
Antimicrobial Assays--
Listeria monocytogenes
EGD, Staphylococcus aureus 502a, Escherichia
coli ML35, Candida albicans 16820, and
Cryptococcus neoformans 271a were used as target organisms
in radial diffusion assays as described previously (43). L. monocytogenes 10403s, L. monocytogenes 967, S. aureus 502a, Salmonella typhimurium GALe, S. typhimurium SH6497 (a polymyxin-resistant strain), E. coli ML35, and C. neoformans 271a were used as target
organisms in microbicidal suspension assays as described previously
(32, 44).
Isolation, Characterization, and Synthesis of
BDP-13--
Approximately 2 × 1010 cell equivalents
of acid-solubilized granule protein was fractionated on a Bio-Gel P-60
column, and the antibacterial activity in pooled eluent fractions was
evaluated by radial diffusion assay (32). One broad P-60 peak that
contained neutrophil bOBP cDNA--
The full-length bOBP cDNA was 688 nucleotides in length and predicted a 190-amino acid precursor protein
(Fig. 1). Within the precursor, the sequence of the first 21 residues
was characteristic of a signal peptide (45, 46), and the predicted
signal peptide cleavage site was confirmed by characterization of
native bOBP (169 amino acids, see below). BDP-13 corresponded to the 13 carboxyl-terminal residues of bOBP.
A BLAST search of GenBankTM identified bOBP to be a member
of the peptidoglycan recognition protein family of proteins. Eight proteins with greatest sequence similarity to bOBP included seven PGRPs
and a butterfly molt protein (Fig. 2).
Four cysteines are completely conserved, and six cysteines are
conserved in the mammalian sequences. The identity of amino acid
sequences to bOBP ranged from 37 to 74%.
Isolation and Characterization of bOBP--
bOBP was purified from
acid extracts of bovine granulocytes and of granule preparations by
RP-HPLC fractionation and immunologic detection with anti-bOBP IgG
(Fig. 3A). Purified bOBP was
homogeneous by RP-HPLC (Fig. 3B), behaved as a single 19-kDa
band on SDS-PAGE (Fig. 3C), and had a mass of 18779.6 by
MALDI-TOF MS. The mass data are consistent with a polypeptide composed
of the 169 carboxyl-terminal residues of the bOBP precursor with
additional modifications including the formation of three disulfides
and the cyclization of glutamine 22 to form pyroglutamic acid at
the amino terminus of the mature protein (theoretical
mass = 18785.3). Consistent with this structure, the amino
terminus was blocked as revealed by automated sequence analysis.
The sequence of a cyanogen-bromide digestion fragment was determined
to be GNYMHRVPPASALRAAQSL (Fig. 1, single
underline). This sequence was identical to bOBP residues
127-145 predicted by the cDNA. The predicted pI of mature bOBP is
9.38 (47).
The average yield of bOBP from 1 × 109 bovine
granulocytes (~400 ml of whole blood) was 2.9 mg. In contrast, no
more than 2.125 µg of BDP-13 was detected in an equivalent number of
granulocytes, indicating that the major form of the bOBP gene product
in leukocytes is the 169 amino acid molecule.
bOBP Disulfide Motif--
RP-HPLC chromatograms of native and
reduced/alkylated tryptic digests of bOBP revealed three peptides that
were modified by reduction and alkylation, indicating the presence of
disulfide bonds. Each of the corresponding peptides obtained from the
native digest was analyzed by MALDI-TOF MS and six steps of Edman
sequencing (Table I). An analysis
of the masses and sequences obtained allowed for the unambiguous
assignment of the cysteine connectivities shown in Fig.
4. The resultant motif of 1-6, 2-5, and
3-4 pairings is consistent with the pattern reported for
Bombyx mori PGRP that contains two disulfides, those
corresponding to the 1-6 and 3-4 pairings in bOBP.
Immunolocalization of bOBP--
Immunohistochemical staining of
bovine peripheral blood leukocytes with rabbit anti-bOBP IgG
demonstrated that bOBP is expressed in eosinophils and neutrophils.
Immunoreactivity was strongest in eosinophils, slightly less in
neutrophils, but absent from lymphocytes and monocytes (Fig.
5). Extracts of purified lymphocytes and
monocytes and of purified platelets were negative for bOBP when
subjected to Western blot analysis (data not shown). The immunostaining
of bovine neutrophils and eosinophils was punctate and cytoplasmic,
consistent with granular storage of bOBP in these cells.
Distribution of bOBP mRNA--
Because bOBP was isolated from
granulocytes of circulating bovine blood, the detection of 0.9-kb bOBP
mRNA in bone marrow extracts was not unexpected (Fig.
6). Six other tissues including liver and
spleen (highly populated by myeloid elements), small intestine, kidney,
lung, and trachea were analyzed and found to contain no detectable bOBP
mRNA (Fig. 6 and data not shown).
Antimicrobial Activities of BDP-13 and bOBP--
The ability of
bOBP and BDP-13 to inhibit the growth of microorganisms was determined
in radial diffusion inhibition assays. Significant zones of inhibition
were observed with 10 µM (190 µg/ml) bOBP against
S. aureus 502a, L. monocytogenes EGD, and E. coli ML35 (Fig. 7). The
fungus, C. neoformans 271a, was less sensitive to bOBP than
bacteria, but an appreciable zone of clearing was apparent at 30 µM (570 µg/ml). The diameters of clearing were dose-dependent, demonstrating log-linear relationships in
the range tested typical of antimicrobial peptides and proteins. At concentrations of 3-100 µM, BDP-13 was inactive against
bacteria and weakly inhibited growth of C. neoformans
at 30 and 100 µM. Neither bOBP nor BDP-13 inhibited the
growth of a second yeast, C. albicans 16820, at
concentrations of up to 100 µM (data not shown).
Antimicrobial suspension assays were used to determine the microbicidal
activities of bOBP. A 2-h incubation with 1.3 µM (25 µg/ml) bOBP induced at least three logs of killing of S. typhimurium SH6497, a polymyxin-resistant strain, and of L. monocytogenes 967 (Fig. 8). S. aureus 502a and L. monocytogenes 10403s were killed by
at least three logs by 2.7 µM bOBP (50 µg/ml), whereas equivalent killing of S. typhimurium GALe required twice as
much protein (Fig. 8). E. coli ML35, although inhibited in
the diffusion assay (Fig. 7), was resistant to bOBP concentrations of
up to 200 µg/ml (10.7 µM) (data not shown). bOBP killed
more than two logs of C. neoformans 271a at 10.7 µM (200 µg/ml) (Fig. 8).
bOBP is a leukocyte-derived member of the PGRP gene family that is
expressed at high levels in circulating neutrophils and eosinophils.
The average yield of bOBP was ~7 mg/liter of adult bovine blood. The
abundance of the protein and the relative ease of purification
facilitated the structural and functional studies described herein.
bOBP is the first vertebrate PGRP for which the amino acid sequence
(Fig. 2) and tri-disulfide structure (Fig. 4) have been determined.
Mass spectroscopic analyses demonstrate that bOBP is not glycosylated
and that the amino terminus is a pyroglutamyl residue. The cystine
motif is consistent with that of the two-disulfide motif of B. mori PGRP (25). In all PGRPs, one disulfide of 1-6 bridges the
amino and carboxyl ends of the chain, and a second disulfide of 3-4
forms a heptapeptide loop, the sequence of which is highly conserved
particularly in mammals (Fig. 2). The third disulfide of 2-5 occurs
only in mammalian PGRPs, introducing an additional degree of backbone
constraint that is absent in the invertebrate orthologs.
An assignment of the PGRP nomenclature to this family of proteins was
rationalized by studies indicating that natural PGRP from B
mori bound to peptidoglycan (27) and that recombinant PGRP from
Trichoplusia ni and from Mus musculus
bound well to peptidoglycan and Gram-positive bacteria but poorly to
Gram-negative bacteria (26, 28). However, our studies demonstrate that
Gram-positive and Gram-negative bacteria and at least one fungus are
killed by bOBP in the 0.5-10 µM range. Antimicrobial
activity of a PGRP has been reported on one previous occasion (26),
i.e. an analysis of recombinant mouse PGRP.
Polyhistidine-tagged murine PGRP inhibited the growth of four
Gram-positive bacteria, Bacillus megaterium, Staphylococcus hemolyticus, Staphylococcus
warneri, and Staphylococcus capitis, but was not
microbicidal (26). The difference between our findings and those
published previously may be attributed to differences between the
murine and bovine proteins and/or the conditions used in the
antimicrobial assays.
We selected the term bOBP for this member of the PGRP family because of
the fact that it kills some microorganisms that lack peptidoglycan
(C. neoformans) or in which the peptidoglycan is obscured by
LPS (e.g. S. typhimurium). Moreover, recombinant
mouse PGRP reportedly binds LPS (26). Preliminary studies in our
laboratory have shown that bOBP binds to each of the microorganisms
that it kills, and it also binds to preparations of microbial antigens including lipopolysaccharide and lipoteichoic acid in addition to
peptidoglycan.2 Also, PGRP is
reported to interact with the glycan moiety of peptidoglycan (26, 27).
Thus, we hypothesize that the binding of bOBP to microbial targets is
mediated by oligosaccharide components present in each of these cell
surface structures, and that the relative binding affinities are
dependent on the composition and stereochemistry of the specific sugar residues.
Thus far, we have detected bOBP in eosinophils and neutrophils but not
monocytes, lymphocytes (Fig. 5), or platelets (data not shown), and
bOBP mRNA was detected only in bone marrow. Immunocytochemical analysis was suggestive of a granular location of bOBP in granulocytes (Fig. 5), and this subcellular localization was further supported by
the purification of bOBP from cytoplasmic granule preparations of
bovine leukocytes. Despite the stronger immunostaining of bOBP in
eosinophils (Fig. 5), quantitative HPLC and immunoblotting assays
demonstrated that neutrophils and eosinophils contain equal quantity of
bOBP per cell (data not shown). Thus, the difference in immunostaining
probably reflects differences in antigen presentation in the cytoplasm
of the two granulocyte populations.
To our knowledge, bOBP is the only microbicidal granule protein other
than bactericidal/permeability-increasing protein and eosinophil
cationic protein that is expressed in eosinophils and neutrophils (48).
Largely considered effectors of antiparasitic immunity, eosinophils are
not recruited to sites of bacterial infection and they possess little
bactericidal activity in vitro. This finding raises the
possibility that bOBP may contribute to the antiparasitic activities of
the eosinophil.
The data presented here provide further evidence for the role of PGRPs
in mammalian innate immunity. Specifically, our studies demonstrated
that (i) bOBP is bactericidal and fungicidal in vitro at low
micromolar concentrations, (ii) bOBP is expressed in the granules of
circulating neutrophils and eosinophils, and (iii) it is an ortholog of
proteins implicated in the immune functions in insects (25, 27, 28).
Although it is apparent that bOBP and other PGRPs recognize microbes by
pattern recognition, additional studies are needed to identify the
molecular determinants of PGRP microbial recognition as well as the
mode of PGRP-mediated antimicrobial action.
*
This work was supported in part by National Institutes of
Health Grant AI22931, Large Scale Biology, Inc., and the Hewitt Foundation.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
The nucleotide and protein sequences reported in this paper have
been reported to the GenBankTM/EBI Data Bank with accession numbers
AY083309 and AAL87002, respectively.
¶
To whom correspondence should be addressed: Dept. of
Pathology, College of Medicine, University of California, Irvine, CA 92697-4800. Tel.: 949-824-2350; E-mail: meselste@uci.edu.
Published, JBC Papers in Press, March 5, 2002, DOI 10.1074/jbc.M200659200
2
C. Chace Tydell, Y. D. Tran, J. Yuan, and
M. E. Selsted, manuscript in preparation.
The abbreviations used are:
LPS, lipopolysaccharide;
PGRP, peptidoglycan recognition protein;
TLR, toll-like receptor;
bOBP, bovine oligosaccharide binding protein;
BDP-13, bOBP-derived peptide-13;
RP-HPLC, reversed-phase high
performance liquid chromatography;
MALDI-TOF MS, matrix-assisted laser
desorption/ionization time-of-flight mass spectroscopy;
GAPDH, glyceraldehyde-3-phosphate dehydrogenase;
Fmoc, N-(9-fluorenyl)methoxycarbonyl;
RACE, rapid amplification of
cDNA ends;
PIPES, 1,4-piperazinediethanesulfonic acid;
Tricine, N-[2-hydroxy-1,1-bis(hydroxymethyl)ethyl]glycine;
TPCK, L-1-tosylamido-2-phenylethyl chloromethyl ketone or
tosylphenylalanyl chloromethyl ketone.
Isolation, Characterization, and Antimicrobial
Properties of Bovine Oligosaccharide-binding Protein
A MICROBICIDAL GRANULE PROTEIN OF EOSINOPHILS AND NEUTROPHILS*
,
,
§,
, and
§¶
Pathology and
§ Microbiology & Molecular Genetics, University of
California, Irvine, California 92697
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
70 °C.
70 °C.
-cyano-4-hydroxycinnamic acid matrix prior to
analysis (38).
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-defensins (32) was further fractionated by
RP-HPLC. BDP-13, later identified as the carboxyl-terminal
tridecapeptide of bOBP, eluted on C18 RP-HPLC as a single
peak at 23 min (32). After a subsequent round of RP-HPLC under slightly
different gradient conditions, pure BDP-13 was obtained which was
homogeneous by analytical RP-HPLC and acid-urea PAGE (data not shown).
Automated sequence analysis was performed providing unambiguous
assignment of the primary sequence of BDP-13, YKIIQQWPHYRRV
(Fig. 1, double-underlined sequence). As discussed below, the sequence was confirmed by
comparison with the bOBP cDNA. Synthetic BDP-13 was used to produce
anti-bOBP antibody (see "Experimental Procedures").

View larger version (38K):
[in a new window]
Fig. 1.
cDNA and deduced precursor sequences of
bOBP (GenBankTM accession numbers AY083309 and AAL87002). The
BDP-13 sequence is double underlined. Internal sequence
obtained following cyanogen bromide digest is underlined.
The signal sequence is shaded.

View larger version (92K):
[in a new window]
Fig. 2.
Sequence alignment of bOBP with other
PGRPs. Orthologs include C.d-PGRP from dromedary camel
(GenBankTM accession number AJ131676), H.s-PGRP-S from
human (GenBankTM accession number AF076483), M.m-PGRP-S
from mouse (GenBankTM accession number AF076482), R.n-PGRP
from rat (GenBankTM accession number AF154114), D.m-PGRP-SA
from Drosophila (GenBankTM accession number
AF207540), T.ni-PGRP from the Cabbage Looper moth
(GenBankTM accession number AF076481), B.m-PGRP from the
Silkworm moth (GenBankTM accession number BAA77209), and
CECP22 from the Brazilian Skipper butterfly (GenBankTM
accession number AF035445). Uppercase letters with a
gray background are identical residues. Conserved cysteines
are boxed. Lowercase letters are non-conserved
amino acids.

View larger version (23K):
[in a new window]
Fig. 3.
Purification of bOBP. A, acid
extract of 6 × 108 bovine granulocytes was
fractionated by RP-HPLC on a DeltaPak C18 cartridge as
described under "Experimental Procedures." Anti-bOBP
immunoreactivity was detected in the peak marked with an
asterisk. B, twelve micrograms of purified bOBP
was analyzed by C18 RP-HPLC using a linear
water/acetonitrile (0.1% trifluoroacetic acid) gradient applied at
1%/min. C, SDS-PAGE of bOBP stained with Coomassie Blue
(left lane) and developed by Western blotting with
anti-BDP-13 IgG (right lane).
Cystine-containing peptides isolated from bOBPa
![]()
View larger version (9K):
[in a new window]
Fig. 4.
Disulfide connectivities of bOBP.
Trypsin-cleavage fragments that contain disulfide bonds are
highlighted. Sequences obtained by Edman degradation
analysis are underlined (see Table I).

View larger version (47K):
[in a new window]
Fig. 5.
Immunolocalization of bOBP in peripheral
leukocytes. An eosinophil-enriched population of
bovine granulocytes was prepared for immunocytochemistry as described
under "Experimental Procedures." Panels A and
B, cells were stained with anti-BDP-13 IgG (see
"Experimental Procedures"). Panel C, cells were stained
with anti-bOBP IgG preabsorbed with synthetic BDP-13 peptide. In each
panel, eosinophils are indicated by a filled arrow, and
neutrophils are indicated by an open arrow. The unlabeled
cells in panel B are mononuclear cells.

View larger version (24K):
[in a new window]
Fig. 6.
Northern blot of bovine tissues.
Expression of bOBP mRNA in bovine tissues was determined by
Northern blot analysis. 20 µg of RNA from bovine bone marrow
(BM), small intestine (SI), trachea
(Tr), liver (L), and spleen (Sp) was
resolved by electrophoresis in a standard 1% agarose, 6% formaldehyde
gel. The membrane was sequentially hybridized under high stringent
conditions with the 32P-labeled full-length bOBP cDNA
and mouse GAPDH cDNA.

View larger version (21K):
[in a new window]
Fig. 7.
Antimicrobial activities of bOBP and
BDP-13. Agar radial diffusion assays were performed using varied
protein concentrations. Activity is expressed as the diameter of
clearing of duplicate samples resulting from the application of 5 µl
of BDP-13 (
) or bOBP (
) against each organism at the indicated
concentrations.

View larger version (26K):
[in a new window]
Fig. 8.
Microbicidal activities of bOBP. Log
phase organisms were incubated with varied concentrations of bOBP in pH
7.4 buffer for 2 h at 37 °C before plating. The incubation
buffers were as follows: 10 mM PIPES with 5 mM
dextrose for L. monocytogenes 967 and L. monocytogenes 10403s; 10 mM PIPES for C. neoformans 271a; 10 mM Tris-HCl with 5 mM
dextrose for S. typhimurium GALe and S. typhimurium SH 6497; and 10 mM Tris for S. aureus 502a. Microbicidal activity was determined by colony
counting of plates after 24-48 h incubation.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
FOOTNOTES
![]()
ABBREVIATIONS
![]()
REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1.
Hoffmann, J. A.,
Kafatos, F. C.,
Janeway, C. A., Jr.,
and Ezekowitz, R. A. B.
(1999)
Science
284,
1313-1318 2.
Medzhitov, R.,
and Janeway, C. J.
(1997)
Cell
91,
295-298[CrossRef][Medline]
[Order article via Infotrieve]
3.
Bogdan, C.,
Rollinghoff, M.,
and Diefenbach, A.
(2000)
Curr. Opin. Immunol.
12,
64-76[CrossRef][Medline]
[Order article via Infotrieve]
4.
Nathan, C.,
and Shiloh, M. U.
(2000)
Proc. Natl. Acad. Sci. U. S. A.
97,
8841-8848 5.
Beamer, L. J.,
Carroll, S. F.,
and Eisenberg, D.
(1999)
Biochem. Pharmacol.
57,
225-229[CrossRef][Medline]
[Order article via Infotrieve]
6.
Tobias, P. S.,
Soldau, K.,
Iovine, N. M.,
Elsbach, P.,
and Weiss, J.
(1997)
J. Biol. Chem.
272,
18682-18685 7.
Calafat, J.,
Janssen, H.,
Knol, E. F.,
Malm, J.,
and Egesten, A.
(2000)
Acta Pathol. Microbiol. Immunol. Scand.
108,
201-208
8.
Weiss, J.,
Elsbach, P.,
Olsson, I.,
and Odeberg, H.
(1978)
J. Biol. Chem.
253,
1664-1672
9.
von der Mohlen, M. A.,
Kimmings, A. N.,
Wedel, N. I.,
Mevissen, M. L.,
Jansen, J.,
Friedmann, N.,
Lorenz, T. J.,
Nelson, B. J.,
White, M. L.,
and Bauer, R.
(1995)
J. Infect. Dis.
172,
144-151[Medline]
[Order article via Infotrieve]
10.
Ulevitch, R. J.,
and Tobias, P. S.
(1995)
Annu. Rev. Immunol.
13,
437-457[CrossRef][Medline]
[Order article via Infotrieve]
11.
Ulevitch, R. J.,
and Tobias, P. S.
(1999)
Curr. Opin. Immunol.
11,
19-22[CrossRef][Medline]
[Order article via Infotrieve]
12.
Lemaitre, B.,
Nicolas, E.,
Michaut, L.,
Reichhart, J.-M.,
and Hoffmann, J. A.
(1996)
Cell
86,
973-983[CrossRef][Medline]
[Order article via Infotrieve]
13.
Kaisho, T.,
and Akira, S.
(2001)
Trends Immunol.
22,
78-83[CrossRef][Medline]
[Order article via Infotrieve]
14.
Medzhitov, R.,
and Janeway, C. J.
(2000)
Trends Microbiol.
8,
452-456[CrossRef][Medline]
[Order article via Infotrieve]
15.
Akira, S.,
Takeda, K.,
and Kaisho, T.
(2001)
Nat. Immunol.
2,
675-680[CrossRef][Medline]
[Order article via Infotrieve]
16.
Schwandner, R.,
Dziarski, R.,
Wesche, H.,
Rothe, M.,
and Kirschning, C. J.
(1999)
J. Biol. Chem.
274,
17406-17409 17.
Poltorak, A., He, X.,
Smirnova, I.,
Liu, M. Y.,
Huffel, C. V., Du, X.,
Birdwell, D.,
Alejos, E.,
Silva, M.,
Galanos, C.,
Freudenberg, M.,
Ricciardi-Castagnoli, P.,
Layton, B.,
and Beutler, B.
(1998)
Science
282,
2085-2088 18.
Qureshi, S. T.,
Lariviere, L.,
Leveque, G.,
Clermont, S.,
Moore, K. J.,
Gros, P.,
and Malo, D.
(1999)
J. Exp. Med.
189,
615-625 19.
Hayashi, F.,
Smith, K. D.,
Ozinsky, A.,
Hawn, T. R., Yi, E. C.,
Goodlett, D. R.,
Eng, J. K.,
Akira, S.,
Underhill, D. M.,
and Aderem, A.
(2001)
Nature
410,
1099-1103[CrossRef][Medline]
[Order article via Infotrieve]
20.
Hemmi, H.,
Takeuchi, O.,
Kawai, T.,
Kaisho, T.,
Sato, S.,
Sanjo, H.,
Matsumoto, M.,
Hoshino, K.,
Wagner, H.,
Takeda, K.,
and Akira, S.
(2000)
Nature
408,
740-745[CrossRef][Medline]
[Order article via Infotrieve]
21.
Turner, M. W.
(1996)
Immunol. Today
17,
532-540[CrossRef][Medline]
[Order article via Infotrieve]
22.
Kuhlman, M.,
Joiner, K.,
and Ezekowitz, R. A.
(1989)
J. Exp. Med.
169,
1733-1745 23.
Summerfield, J. A.,
Ryder, S.,
Sumiya, M.,
Thursz, M.,
Gorchein, A.,
Monteil, M. A.,
and Turner, M. W.
(1995)
Lancet
345,
886-889[CrossRef][Medline]
[Order article via Infotrieve]
24.
Liu, C., Xu, Z.,
Gupta, D.,
and Dziarski, R.
(2001)
J. Biol. Chem.
276,
34686-34694 25.
Ochiai, M.,
and Ashida, M.
(1999)
J. Biol. Chem.
274,
11854-11858 26.
Liu, C.,
Gelius, E.,
Liu, G.,
Steiner, H.,
and Dziarski, R.
(2000)
J. Biol. Chem.
275,
24490-24499 27.
Yoshida, H.,
Kinoshita, K.,
and Ashida, M.
(1996)
J. Biol. Chem.
271,
13854-13860 28.
Kang, D.,
Liu, G.,
Lundstrom, A.,
Gelius, E.,
and Steiner, H.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
10078-10082 29.
Marcu, O.,
and Locke, M.
(1998)
Insect Biochem. Mol. Biol.
28,
659-669[CrossRef][Medline]
[Order article via Infotrieve]
30.
Marcu, O.,
and Locke, M.
(1999)
J. Insect Physiol.
45,
861-870[CrossRef][Medline]
[Order article via Infotrieve]
31.
Werner, T.,
Liu, G.,
Kang, D.,
Ekengren, S.,
Steiner, H.,
and Hultmark, D.
(2000)
Proc. Natl. Acad. Sci. U. S. A.
97,
13772-13777 32.
Selsted, M. E.,
Tang, Y.-Q.,
Morris, W. L.,
McGuire, P. A.,
Novotny, M. J.,
Smith, W.,
Henschen, A. H.,
and Cullor, J. S.
(1993)
J. Biol. Chem.
268,
6641-6648 33.
Amrein, P. C.,
and Stossel, T. P.
(1980)
Blood
56,
442-447 34.
Borregaard, N.,
Heiple, J. M.,
Simons, E. R.,
and Clark, R. A.
(1983)
J. Cell Biol.
97,
52-61 35.
Barany, G.,
Sole, N. A.,
Van Abel, R. J.,
Albericio, F.,
and Selsted, M. E.
(1992)
in
Innovation and Perspectives in Solid Phase Synthesis and Related Technologies: Peptides, Polypeptides and Oligonucleotides
(Epton, R., ed)
, pp. 29-38, Intercept, Andover, United Kingdom
36.
Van Abel, R. J.,
Tang, Y.-Q.,
Rao, V. S. V.,
Dobbs, C. H.,
Tran, D.,
Barany, G.,
and Selsted, M. E.
(1995)
Int. J. Pept. Protein Res.
45,
401-409[Medline]
[Order article via Infotrieve]
37.
Yount, N. Y.,
Wang, M.-S. C.,
Yuan, J.,
Banaiee, N.,
Ouellette, A. J.,
and Selsted, M. E.
(1995)
J. Immunol.
155,
4476-4484[Abstract]
38.
Hillenkamp, F.,
Karas, M.,
Beavis, R. C.,
and Chait, B. T.
(1991)
Anal. Chem.
63,
1193A-1203A[Medline]
[Order article via Infotrieve]
39.
Chomczynski, P.,
and Sacchi, N.
(1987)
Anal. Biochem.
162,
156-159[Medline]
[Order article via Infotrieve]
40.
Wilkins, M. R.,
Lindskog, I.,
Gasteiger, E.,
Bairoch, A.,
Sanchez, J. C.,
Hochstrasser, D. F.,
and Appel, R. D.
(1997)
Electrophoresis
18,
403-408[CrossRef][Medline]
[Order article via Infotrieve]
41.
Jacobson, G.
(1990)
Electrophoresis
11,
46-52[CrossRef][Medline]
[Order article via Infotrieve]
42.
Yount, N. Y.,
Yuan, J.,
Tarver, A.,
Castro, T.,
Diamond, G.,
Tran, P. A.,
Levy, J. N.,
McCullough, C.,
Cullor, J. S.,
Bevins, C. L.,
and Selsted, M. E.
(1999)
J. Biol. Chem.
274,
26249-26258 43.
Lehrer, R. I.,
Rosenman, M.,
Harwig, S. S. L.,
Jackson, R.,
and Eisenhauer, P.
(1991)
J. Immunol. Methods
137,
167-173[CrossRef][Medline]
[Order article via Infotrieve]
44.
Selsted, M. E.,
Szklarek, D.,
and Lehrer, R. I.
(1984)
Infect. Immun.
45,
150-154 45.
Nielsen, H.,
Engelbrecht, J.,
Brunak, S.,
and Von Heijne, G.
(1997)
Protein Eng.
10,
1-16 46.
Von Heijne, G.
(1983)
Eur. J. Biochem.
133,
17-21[Medline]
[Order article via Infotrieve]
47.
Bjellqvist, B.,
Hughes, G. J.,
Pasquali, C.,
Paquet, N.,
Ravier, F.,
Sanchez, J. C.,
Frutiger, S.,
and Hochstrasser, D.
(1993)
Electrophoresis
14,
1023-1031[CrossRef][Medline]
[Order article via Infotrieve]
48.
Calafat, J.,
Janssen, H.,
Tool, A.,
Dentener, M. A.,
Knol, E. F.,
Rosenberg, H. F.,
and Egesten, A.
(1998)
Blood
91,
4770-4775
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
J. D. Lippolis Immunological signaling networks: Integrating the body's immune response J Anim Sci, April 1, 2008; 86(14_suppl): E53 - E63. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Wang, L.-H. Liu, S. Wang, X. Li, X. Lu, D. Gupta, and R. Dziarski Human Peptidoglycan Recognition Proteins Require Zinc to Kill Both Gram-Positive and Gram-Negative Bacteria and Are Synergistic with Antibacterial Peptides J. Immunol., March 1, 2007; 178(5): 3116 - 3125. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Li, S. Wang, H. Wang, and D. Gupta Differential Expression of Peptidoglycan Recognition Protein 2 in the Skin and Liver Requires Different Transcription Factors J. Biol. Chem., July 28, 2006; 281(30): 20738 - 20748. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Lu, M. Wang, J. Qi, H. Wang, X. Li, D. Gupta, and R. Dziarski Peptidoglycan Recognition Proteins Are a New Class of Human Bactericidal Proteins J. Biol. Chem., March 3, 2006; 281(9): 5895 - 5907. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. S. Garver, J. Wu, and L. P. Wu The peptidoglycan recognition protein PGRP-SC1a is essential for Toll signaling and phagocytosis of Staphylococcus aureus in Drosophila PNAS, January 17, 2006; 103(3): 660 - 665. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. C. Tydell, J. Yuan, P. Tran, and M. E. Selsted Bovine Peptidoglycan Recognition Protein-S: Antimicrobial Activity, Localization, Secretion, and Binding Properties J. Immunol., January 15, 2006; 176(2): 1154 - 1162. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Kumar, A. Roychowdhury, B. Ember, Q. Wang, R. Guan, R. A. Mariuzza, and G.-J. Boons Selective Recognition of Synthetic Lysine and meso-Diaminopimelic Acid-type Peptidoglycan Fragments by Human Peptidoglycan Recognition Proteins I{alpha} and S J. Biol. Chem., November 4, 2005; 280(44): 37005 - 37012. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Sang, B. Ramanathan, C. R. Ross, and F. Blecha Gene Silencing and Overexpression of Porcine Peptidoglycan Recognition Protein Long Isoforms: Involvement in {bet |